List of Excipients in Branded Drug TORISEL

# Torisel Excipient Strategy and Commercial Opportunities in Temsirolimus Injection

Last updated: August 13, 2026

Torisel is an intravenous temsirolimus product for advanced renal cell carcinoma. Its commercial opportunity is concentrated in formulation simplification, excipient substitution, ready-to-use delivery, supply-chain reliability, and hospital cost reduction rather than biosimilar development. The reference product uses a solvent-intensive presentation containing ethanol, propylene glycol, polysorbate 80, citric acid, sodium hydroxide, and a separate diluent. That configuration creates opportunities for a generic or 505(b)(2) sponsor to reduce preparation steps, improve stability, and lower occupational and administration burdens while preserving the same weekly intravenous dose.

The principal technical barrier is temsirolimus’s poor aqueous solubility and sensitivity to formulation conditions. Any alternative must maintain chemical stability, prevent precipitation after dilution, control extractables and leachables, and demonstrate compatibility with infusion bags and administration sets.

What is Torisel and how is it administered?

Torisel is the Pfizer-developed brand of temsirolimus, an mTOR inhibitor. The FDA approved it on May 30, 2007, for the treatment of advanced renal cell carcinoma. The recommended dose is 25 mg administered intravenously over approximately 30 to 60 minutes once weekly.[1]

The marketed presentation is a two-vial system:

Product attribute	Torisel reference presentation
Active ingredient	Temsirolimus
Dosage form	Intravenous concentrate requiring dilution
Vial strength	30 mg temsirolimus in 1.2 mL concentrate
Nominal concentration	25 mg/mL before dilution
Diluent	Separate manufacturer-supplied diluent
Administration	Further dilution in 0.9% sodium chloride
Dose	25 mg IV once weekly
Primary indication	Advanced renal cell carcinoma
FDA approval	May 30, 2007
Reference sponsor	Wyeth Pharmaceuticals, later within Pfizer
Biosimilar pathway	Not applicable; temsirolimus is a small molecule

The label requires aseptic preparation and staged dilution. The product must be visually inspected for particulate matter and discoloration before administration. The final infusion solution is prepared in normal saline and is not intended for direct intravenous injection.[1]

What excipients are used in Torisel?

The Torisel concentrate uses a mixed-solvent and surfactant system. The principal excipient functions are summarized below.

Excipient or formulation component	Function in the product	Commercial significance
Ethanol	Co-solvent for temsirolimus	Creates handling, flammability, tolerability, and container-closure considerations
Propylene glycol	Co-solvent and vehicle	Supports solubilization but can increase osmolality and infusion-related concerns
Polysorbate 80	Surfactant and solubilizer	Helps prevent precipitation but can generate peroxide-related degradation products
Citric acid	pH adjustment and buffering	Controls formulation pH and contributes to stability
Sodium hydroxide	pH adjustment	Provides final pH control
Sodium chloride	Dilution medium after preparation	Used for the final infusion solution

The separate diluent is a central design feature. It allows the highly concentrated temsirolimus formulation to remain in a small-volume vial, but it adds inventory, preparation time, labeling complexity, and opportunities for compounding error.[1]

Why is polysorbate 80 important in temsirolimus formulation?

Polysorbate 80 improves wetting and solubilization of hydrophobic drug material. Its drawbacks include oxidative degradation, peroxide formation, potential interaction with proteins or other formulation components, and variability between suppliers and grades.

For a temsirolimus product, a sponsor replacing polysorbate 80 would need to show that the replacement maintains:

• Drug solubility throughout shelf life.
• Resistance to precipitation after saline dilution.
• Acceptable subvisible particle levels.
• Compatibility with the vial, stopper, syringe, infusion bag, and tubing.
• Equivalent or improved impurity profiles.
• Consistent performance after temperature excursions.

Possible replacement systems include polysorbate 20, poloxamers, lipid-based solubilizers, cyclodextrin complexes, or mixed surfactant systems. Each creates a different regulatory and patent profile.

What excipient strategy offers the strongest commercial opportunity?

The strongest commercial strategy is a ready-to-use or simplified-concentration product that removes the separate diluent step without introducing a new administration burden.

1. Ready-to-dilute single-vial formulation

A single vial containing a stable temsirolimus concentrate could eliminate the separate diluent vial. This would reduce preparation steps and simplify pharmacy inventory. The formulation would still require further dilution into normal saline unless the sponsor develops a true premixed infusion.

Potential advantages include:

• Lower pharmacy labor.
• Fewer preparation errors.
• Reduced risk of incorrect diluent selection.
• Lower packaging and inventory costs.
• Easier hospital formulary adoption.
• More efficient use in outpatient infusion centers.

A single-vial product may be eligible for an abbreviated application if it demonstrates pharmaceutical equivalence and bioequivalence. A materially different formulation, concentration, route, or presentation could instead require a 505(b)(2) strategy.

2. Low-ethanol or ethanol-free formulation

The reference formulation’s ethanol content creates a clear development target. Ethanol-free or low-ethanol temsirolimus could improve handling and reduce concerns relating to flammability, odor, occupational exposure, and patient exposure.

The technical issue is solvent replacement. Temsirolimus has limited water solubility, so removing ethanol may require:

• A higher surfactant level.
• A cyclodextrin complex.
• A lipid or emulsion system.
• A different pH range.
• A higher concentration of propylene glycol.
• Nanoparticle or amorphous dispersion technology.

A low-ethanol formulation has commercial value, but a major excipient change may create a new product rather than a simple generic equivalent. That can support 505(b)(2) positioning and potentially create formulation patent claims.

3. Propylene-glycol reduction

Propylene glycol supports solubilization but contributes to osmolality and total solvent burden. Reducing its concentration could improve tolerability and simplify formulation labeling.

The main development risk is precipitation during dilution. Temsirolimus can remain soluble in the concentrate but precipitate when the solvent composition changes in the infusion bag. A sponsor would need robust dilution studies across:

• Dose concentrations.
• Infusion bag sizes.
• Dilution temperatures.
• Hold times before administration.
• Bag materials.
• Administration-set materials.

4. Premixed infusion product

A premixed temsirolimus infusion could offer the greatest workflow benefit. It would also create the highest technical burden because the drug must remain stable at low concentration in a large aqueous volume.

The product would require evaluation of:

• Long-term stability in the final infusion medium.
• Adsorption to polyolefin or PVC bags.
• Interaction with tubing and filters.
• Microbial control.
• Light sensitivity.
• Shipping and storage conditions.
• In-use stability after removal from controlled refrigeration.

A premixed product could be commercially differentiated in hospitals, but it may be difficult to qualify as pharmaceutically equivalent to the reference concentrate. The regulatory pathway would likely depend on the extent of formulation and presentation differences.

What formulation patents could protect an improved Torisel product?

An improved temsirolimus product could be protected through formulation, manufacturing, packaging, and use claims. The most defensible patent positions would generally relate to a defined technical result rather than the use of conventional excipients alone.

Potential claim categories include:

Patent category	Example claim focus
Solvent system	Defined ethanol, propylene glycol, and water ratios that maintain temsirolimus solubility
Surfactant system	Polysorbate, poloxamer, cyclodextrin, or mixed-solubilizer composition
Stability	Reduced degradation after dilution or storage
Dilution method	A specified sequence, concentration, temperature, or infusion medium
Container closure	Vial, stopper, coating, or oxygen-control configuration
Premixed product	Temsirolimus concentration and stability in a ready-to-administer bag
Manufacturing process	Controlled temperature, mixing order, filtration, or oxygen exposure
Particle control	Limits on subvisible particles or precipitation after dilution
Administration	A dosing or infusion method tied to the improved formulation

Patent strength would depend on whether the formulation produces unexpected stability, reduced precipitation, improved tolerability, or a meaningful preparation advantage. A claim covering only a routine substitution of one pharmaceutically acceptable solvent for another would face greater obviousness risk.

What patent barriers affect a generic temsirolimus product?

The original temsirolimus composition and use patents are separate from later formulation patents. Patent expiry for early composition or use claims does not eliminate risk from later patents directed to:

• Specific solvent concentrations.
• Dilution procedures.
• Container systems.
• Stability-enhancing excipient combinations.
• Manufacturing controls.
• Pediatric or supplemental indications.

A sponsor should conduct a current Orange Book review for the Torisel NDA, together with a broader patent search covering temsirolimus formulations and manufacturing processes. The Orange Book controls listed patents relevant to FDA approval, but it does not provide a complete picture of every enforceable formulation or process claim.

What is the Orange Book status of Torisel?

Torisel is associated with FDA NDA 022088. The relevant regulatory questions are whether the reference product remains listed, which patents are currently recorded against the NDA, and whether any listed exclusivity or patent certifications affect approval timing.[2]

For a generic applicant, the key legal pathways are:

1. Paragraph I certification if no patent information is listed.
2. Paragraph II certification if listed patents have expired.
3. Paragraph III certification if the applicant will wait for patent expiry.
4. Paragraph IV certification if the applicant asserts that listed patents are invalid, unenforceable, or not infringed.

The applicant must also assess whether the proposed product can be approved as therapeutically equivalent to the reference listed drug. A different concentration, diluent, route, or administration profile can complicate an ANDA strategy and increase the relevance of a 505(b)(2) application.

When does Torisel lose exclusivity?

The principal regulatory exclusivity periods for Torisel have expired. The product was approved in 2007, and its orphan-drug exclusivity period would have ended approximately seven years after approval, subject to the scope of the designated indication.[1,3]

The commercial exclusivity position should therefore be assessed through current patent listings, regulatory status, product availability, and the feasibility of an ANDA or 505(b)(2) application. Temsirolimus does not create a biosimilar exclusivity issue because it is a chemically synthesized small molecule rather than a biologic.

Which companies are challenging Torisel?

The public competitive field is less active than for major oral oncology products. Torisel competes clinically with other renal cell carcinoma therapies, including:

• Everolimus, marketed as Afinitor.
• Sunitinib, marketed as Sutent.
• Pazopanib, marketed as Votrient.
• Cabozantinib, marketed as Cabometyx.
• Lenvatinib, marketed as Lenvima, often used in combination with everolimus.
• Immune checkpoint inhibitor regimens used in earlier treatment lines.

These products are not direct formulation substitutes in every clinical setting. Their presence limits the addressable market for a temsirolimus generic, but a lower-cost injectable product could retain use where physicians select temsirolimus based on treatment history, patient characteristics, or formulary economics.[4]

No biosimilar entrant is relevant. Competitive pressure would arise from generic temsirolimus, alternative mTOR inhibitors, and clinical migration toward newer combination regimens.

What generic launch risks exist for temsirolimus?

A generic launch would face five principal risks.

Limited market size

Advanced renal cell carcinoma treatment has shifted toward immunotherapy and targeted combinations. This reduces the volume available for a legacy injectable mTOR inhibitor.

Hospital purchasing pressure

Injectable oncology products are often purchased through group purchasing organizations and specialty distributors. A lower list price does not guarantee market share if the product has supply or preparation disadvantages.

Formulation complexity

A conventional concentrate must meet strict dilution and stability requirements. A sponsor with an unstable formulation may experience product waste, recalls, or pharmacy rejection.

Small manufacturing scale

Temsirolimus may not support large-scale API procurement. Small-batch production can produce unfavorable cost of goods and increase dependence on specialized suppliers.

Patent certification exposure

A Paragraph IV strategy can accelerate market access but may trigger litigation under the Hatch-Waxman framework. A Paragraph III strategy reduces litigation risk but delays commercial entry.

How can excipient manufacturers capture value from Torisel?

Excipient suppliers can pursue opportunities even without marketing a finished drug.

Pharmaceutical-grade polysorbate and alternative surfactants

A supplier with low-peroxide polysorbate 80, high-purity poloxamer, or a proprietary surfactant system could target temsirolimus developers seeking improved stability.

Cyclodextrin and solubilization platforms

A cyclodextrin-based system could support ethanol reduction or elimination. The strongest commercial position would come from a platform with established parenteral regulatory precedent and data on injectable compatibility.

Container-closure systems

Drug manufacturers may need low-extractable elastomers, oxygen-controlled closures, coated stoppers, or light-protective packaging. These components can be protected through combination patents and supply agreements.

Ready-to-use infusion technology

A company that provides a stable premix platform could license formulation know-how, analytical methods, and manufacturing processes to a generic or specialty pharmaceutical sponsor.

Contract development and manufacturing

Because the market is specialized, a CDMO could offer an integrated package covering API handling, aseptic filling, dilution stability, container testing, and regulatory support.

How does Torisel compare with Afinitor from an excipient and commercial perspective?

Torisel and Afinitor are both mTOR-pathway products but present different commercial opportunities.

Attribute	Torisel	Afinitor
Active ingredient	Temsirolimus	Everolimus
Primary delivery	Intravenous	Oral tablets and other oral presentations
Formulation challenge	Solubilization and dilution stability	Solid-state, dissolution, and oral bioavailability
Administration burden	Pharmacy preparation and infusion	Patient self-administration
Biosimilar risk	None	None
Generic opportunity	Injectable formulation and workflow	Oral generic manufacturing and bioequivalence
Main commercial advantage	Potential for hospital cost and preparation improvements	Convenience and broader oral use
Main commercial disadvantage	Narrower market and infusion burden	Greater exposure to oral generic competition

Torisel’s formulation opportunity is more technically difficult but can produce stronger differentiation if a sponsor eliminates the two-vial preparation process. Afinitor’s opportunity is more directly tied to oral generic economics.

What FDA regulatory pathway is most suitable for a new temsirolimus product?

An ANDA is most suitable when the proposed product matches the reference product in active ingredient, dosage form, strength, route, and key performance characteristics. The applicant would need to address pharmaceutical equivalence, bioequivalence, labeling, microbiological quality, and container closure.

A 505(b)(2) application may be more appropriate for:

• A single-vial presentation.
• A new solvent system.
• A premixed infusion.
• A different concentration.
• A new container or delivery system.
• A formulation with reduced ethanol or propylene glycol.
• A new stability profile or administration procedure.

A 505(b)(2) application can support differentiated labeling and formulation patents, but it generally requires more clinical or bridging justification than a conventional ANDA.

What manufacturing and IP barriers affect commercial development?

The main manufacturing barrier is control of precipitation during dilution and infusion. Development teams must characterize the product across the full preparation sequence rather than testing only the undiluted concentrate.

Critical controls include:

• Drug concentration in the concentrate.
• Solvent composition and water content.
• Mixing order.
• Temperature during compounding.
• Oxygen exposure.
• Filter compatibility.
• Particulate formation.
• In-use hold time.
• Light exposure.
• Container adsorption.
• Excipient peroxide levels.

The strongest IP position would combine formulation claims with process controls and packaging claims. A standalone excipient claim is less defensible when the ingredient is already widely used in injectable products.

What revenue exposure does Torisel create for Pfizer?

Pfizer does not generally report Torisel revenue as a separate material line item in its consolidated public financial reporting. The product is part of a broader oncology portfolio and is commercially smaller than Pfizer’s major oncology brands.

For a potential entrant, the relevant opportunity is therefore not a large branded-revenue displacement case. It is a niche injectable oncology opportunity based on:

• Manufacturing efficiency.
• Reduced pharmacy preparation.
• Contracting with hospitals.
• Reliable supply.
• Improved storage or handling.
• Specialty distribution.
• A differentiated 505(b)(2) formulation.

Key Takeaways

• Torisel is an intravenous temsirolimus product approved by the FDA in 2007 for advanced renal cell carcinoma.
• Its formulation uses ethanol, propylene glycol, polysorbate 80, citric acid, sodium hydroxide, and a separate diluent.
• The two-vial presentation creates the clearest commercial opportunity for a single-vial or ready-to-dilute product.
• Ethanol reduction, propylene-glycol reduction, low-peroxide surfactants, and premixed infusion systems are viable formulation-development targets.
• Temsirolimus has no biosimilar issue because it is a small molecule.
• An ANDA is appropriate for a close equivalent; a materially different formulation may require a 505(b)(2) application.
• Patent value is strongest where an excipient change produces unexpected stability, reduced precipitation, improved tolerability, or measurable pharmacy workflow benefits.
• Market size is constrained by competition from newer renal cell carcinoma regimens and other mTOR-pathway products.
• The most practical commercial model is a low-cost, reliable hospital injectable with simpler preparation and strong supply performance.

FAQs

Is Torisel a biologic that can face biosimilar competition?

No. Torisel contains temsirolimus, a chemically synthesized small molecule. Future competition would generally involve generic or 505(b)(2) products rather than biosimilars.

Can a manufacturer remove ethanol from Torisel?

Potentially. Ethanol removal would require a replacement solubilization system and extensive testing for precipitation, stability, compatibility, and bioequivalence. The change could support a differentiated 505(b)(2) product.

What is the most valuable Torisel formulation improvement?

A stable single-vial or premixed presentation is likely the most commercially valuable improvement because it can reduce pharmacy preparation steps and administration risk.

Is temsirolimus suitable for a 505(b)(2) application?

Yes. A 505(b)(2) strategy may be appropriate for a new solvent system, premixed infusion, different concentration, or delivery presentation that differs materially from the reference product.

What excipient patent claims are most defensible for temsirolimus?

Claims tied to unexpected stability, prevention of precipitation after dilution, reduced degradation, improved container compatibility, or a specific manufacturing sequence are generally stronger than claims covering routine excipient substitution alone.

References

1. U.S. Food and Drug Administration. (2007). Torisel (temsirolimus) injection prescribing information. Wyeth Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Orphan drug designations and approvals database. https://www.accessdata.fda.gov/scripts/op приб

4. National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. NCCN.